Burroughs Wellcome Fund

January 16, 2024

‘Molecular Muse’ exhibit features Artist-in-Residence program’s science-inspired art

The “Molecular Muse” art exhibit on display in Light Hall is a sampling of pieces from the Vanderbilt Institute for Infection, Immunology and Inflammation Artist-in-Residence (VI4-AiR) program, which brings together scientists and artists to create and promote art as a visual science communication tool.

January 10, 2023

Anti-nausea drug response in children

Genetic variation in a metabolic enzyme was not associated with response to the anti-nausea drug odansetron in children, Vanderbilt researchers report.

Research by Christopher Peek, PhD, left, Jim Cassat, MD, PhD, and their colleagues reveals how gut inflammation leads to bone loss.
August 25, 2022

Vanderbilt researchers discover how gut inflammation leads to bone loss

Gastrointestinal inflammation, such as occurs in inflammatory bowel disease, triggers the expansion of a population of “bone-eating” cells, leading to bone loss.

August 16, 2022

Nanoparticles boost anti-cancer immunity

An ingenious targeted nanoparticle approach developed by Vanderbilt researchers reduced tumor burden in a model of ovarian cancer.

June 2, 2022

Bacterial battle in 3D

Using imaging mass spectrometry and microscopy, Vanderbilt researchers visualized how staph bacteria modifies lipids in its membrane to evade immune system-mediated killing.

May 19, 2022

A clue to an adverse drug event in children

Considering metabolic (CYP2D6) enzyme activity score and patient age may aid in determining an individual’s risk for an adverse event with administration of the anti-arrhythmic drug propafenone.